Axsome Therapeutics Inc.
Moat Score — Axsome Therapeutics Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Axsome holds patent protection on Auvelity's novel dextromethorphan-bupropion combination and on Sunosi's formulation, along with clinical data supporting differentiated mechanisms of action that competitors cannot simply replicate without their own trials. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a mid-sized commercial-stage biopharma, Axsome does not have a manufacturing or scale cost advantage over larger pharmaceutical competitors, and its cost structure is typical of a company still building out commercial infrastructure. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Patent-protected exclusivity on Auvelity and Sunosi allows Axsome to sustain branded pricing during its exclusivity window, though payer formulary negotiations and eventual generic competition will constrain long-term pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Axsome's business model; product adoption is driven by clinical differentiation, prescriber relationships, and payer coverage rather than by any user or participant network. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once psychiatrists and patients achieve good clinical response with Auvelity or Sunosi, there is some inertia against switching therapies, though CNS prescribers can and do move patients between alternative branded and generic options based on individual response and cost. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Axsome operates at a smaller commercial scale than large CNS/psychiatry franchises run by companies like Johnson & Johnson or Otsuka/Lundbeck, meaning it does not yet benefit from a dominant efficient-scale position in its therapeutic categories. |